CCT365623 hydrochloride - CAS:2126136-98-7

您当前的位置：

CCT365623 hydrochloride

目录号 : KM3021 CAS No. : 2126136-98-7 纯度 : 98%

Data Sheet 产品使用指南

CCT365623 hydrochloride 是具有口服活性的赖氨酰氧化酶 (LOX) 抑制剂，其IC₅₀ 值为0.89 μM。CCT365623 hydrochloride 通过驱动EGF抑制EGFR (pY1068) 和 AKT 的磷酸化。CCT365623 hydrochloride 具有极好的耐受性，良好的药理学特性。

规格	价格	是否有货
1mg		In-stock
5mg		In-stock
10mg	询价	In-stock
50mg	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Ginkgolide B In-stock
Isoginkgetin In-stock
Ginkgolic acid C17:1 In-stock
Ginkgolic Acid In-stock
Propargyl-PEG4-amine In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

CCT365623 hydrochloride is an orally active lysyl oxidase (LOX) inhibitor, with an IC₅₀ of 0.89 μM. CCT365623 hydrochloride suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 hydrochloride is extremely well tolerated, and has good pharmacokinetic properties.

体外研究

CCT365623 inhibits LOX at ~5 μM in the biosensor system.
CCT365623 (0-40 μM) concentration-dependently decreases the protein levels of surface EGFR.
CCT365623 (5 μM) decreases the protein levels of pY1068 EGFR, pAKT and MATN2, and increases the protein levels of pSMAD2.
CCT365623 disrupts HTRA1 multimerization, activates TGFβ1 signalling, suppresses MATN2 expression, suppresses EGFR surface retention, and suppresses EGFR signalling.

Western Blot Analysis

Cell Line:	MDA-MB-231 cells.
Concentration:	0-40 μM.
Incubation Time:	24 hours
Result:	Significantly decreased the protein levels of surface EGFR, pY1068 EGFR, pAKT and MATN2. Increased the protein levels of pSMAD2.

体内研究

CCT365623 displays good stability in mouse liver microsomes and does not inhibit the cardiac potassium channel hERG.
CCT365623 (70 mg/kg, oral gavage per day) significantly delays the development of the primary tumors and also suppresses metastatic lung burden in the animals. CCT365623 disrupts EGFR cell surface retention and delays the growth of primary and metastatic tumor cell.
CCT365623 exhibits a T_1/2PO of 0.6 h and F% (oral bioavailability) of 45%.

Animal Model:	Mouse model of spontaneous breast cancer that metastasizes to the lungs (70 days old).
Dosage:	70 mg/kg.
Administration:	Oral gavage per day for about 3 weeks.
Result:	Significantly reduced MATN2 protein levels in both the primary and metastatic lung tumors and this is accompanied by the loss of EGFR from the plasma membranes of the cells in both the primary and metastatic tumors.

分子式

C₁₈H₁₈ClNO₄S₃

分子量

443.99

CAS号

2126136-98-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 250 mg/mL (563.08 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2523 mL	11.2615 mL	22.5230 mL
5 mM	0.4505 mL	2.2523 mL	4.5046 mL
10 mM	0.2252 mL	1.1262 mL	2.2523 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.68 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.68 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.68 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。